JP7175198B2 - 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 - Google Patents

難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 Download PDF

Info

Publication number
JP7175198B2
JP7175198B2 JP2018563008A JP2018563008A JP7175198B2 JP 7175198 B2 JP7175198 B2 JP 7175198B2 JP 2018563008 A JP2018563008 A JP 2018563008A JP 2018563008 A JP2018563008 A JP 2018563008A JP 7175198 B2 JP7175198 B2 JP 7175198B2
Authority
JP
Japan
Prior art keywords
antibody
administered
dose
months
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018563008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517504A (ja
JP2019517504A5 (OSRAM
Inventor
ベネデット・ファルサチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59067911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7175198(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019517504A publication Critical patent/JP2019517504A/ja
Publication of JP2019517504A5 publication Critical patent/JP2019517504A5/ja
Priority to JP2022178836A priority Critical patent/JP7568698B2/ja
Application granted granted Critical
Publication of JP7175198B2 publication Critical patent/JP7175198B2/ja
Priority to JP2024174007A priority patent/JP2025020119A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018563008A 2016-06-02 2017-06-01 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 Active JP7175198B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022178836A JP7568698B2 (ja) 2016-06-02 2022-11-08 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断
JP2024174007A JP2025020119A (ja) 2016-06-02 2024-10-03 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344880P 2016-06-02 2016-06-02
US62/344,880 2016-06-02
PCT/US2017/035492 WO2017210453A1 (en) 2016-06-02 2017-06-01 Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022178836A Division JP7568698B2 (ja) 2016-06-02 2022-11-08 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断

Publications (3)

Publication Number Publication Date
JP2019517504A JP2019517504A (ja) 2019-06-24
JP2019517504A5 JP2019517504A5 (OSRAM) 2020-07-09
JP7175198B2 true JP7175198B2 (ja) 2022-11-18

Family

ID=59067911

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018563008A Active JP7175198B2 (ja) 2016-06-02 2017-06-01 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断
JP2022178836A Active JP7568698B2 (ja) 2016-06-02 2022-11-08 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断
JP2024174007A Pending JP2025020119A (ja) 2016-06-02 2024-10-03 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022178836A Active JP7568698B2 (ja) 2016-06-02 2022-11-08 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断
JP2024174007A Pending JP2025020119A (ja) 2016-06-02 2024-10-03 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断

Country Status (17)

Country Link
US (3) US11083790B2 (OSRAM)
EP (2) EP3463457B1 (OSRAM)
JP (3) JP7175198B2 (OSRAM)
KR (2) KR20190015377A (OSRAM)
CN (1) CN109475633A (OSRAM)
DK (1) DK3463457T3 (OSRAM)
ES (1) ES2954139T3 (OSRAM)
FI (1) FI3463457T3 (OSRAM)
HR (1) HRP20230864T1 (OSRAM)
HU (1) HUE062398T2 (OSRAM)
LT (1) LT3463457T (OSRAM)
PL (1) PL3463457T3 (OSRAM)
PT (1) PT3463457T (OSRAM)
RS (1) RS64388B1 (OSRAM)
SI (1) SI3463457T1 (OSRAM)
SM (1) SMT202300290T1 (OSRAM)
WO (1) WO2017210453A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018000768A2 (pt) 2015-07-13 2018-09-25 Cytomx Therapeutics Inc anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
AU2016305697B2 (en) 2015-08-11 2023-02-02 WuXi Biologics Ireland Limited Novel anti-PD-1 antibodies
KR20190015377A (ko) 2016-06-02 2019-02-13 브리스톨-마이어스 스큅 컴퍼니 불응성 호지킨 림프종에서의 니볼루맙을 사용한 pd-1 차단
FI3464368T3 (fi) 2016-06-02 2023-09-12 Bristol Myers Squibb Co Anti-pd-1-vasta-aineen käyttö yhdistelmänä anti-cd30-vasta-aineen kanssa lymfooman hoitamisessa
CN111770936A (zh) * 2018-01-12 2020-10-13 百时美施贵宝公司 抗il-8抗体和抗pd-1抗体联合治疗用于治疗癌症
MA51844A (fr) * 2018-02-13 2021-05-19 Merck Sharp & Dohme Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4
CN113164599B (zh) * 2018-12-24 2023-08-01 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
EP3946625A1 (en) * 2019-03-28 2022-02-09 Bristol-Myers Squibb Company Methods of treating tumor
WO2025136845A1 (en) * 2023-12-19 2025-06-26 Merck Sharp & Dohme Llc Methods of treating a patient with a pd-1 antagonist

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518826A (ja) 2012-05-15 2015-07-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔ Ｐｄ−１／ｐｄ−ｌ１シグナル伝達を破壊することによる癌免疫療法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
DK1210428T3 (en) 1999-08-23 2015-06-15 Dana Farber Cancer Inst Inc PD-1, a receptor for B7-4 AND USE THEREOF
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
EP1537878B1 (en) 2002-07-03 2010-09-22 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US20060032289A1 (en) 2004-08-11 2006-02-16 Pinnaduwage Lal A Non-optical explosive sensor based on two-track piezoresistive microcantilever
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
MX360254B (es) 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
WO2014028560A2 (en) * 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
PT2992017T (pt) 2013-05-02 2021-01-29 Anaptysbio Inc Anticorpos dirigidos contra a morte programada 1 (pd-1)
HK1221964A1 (zh) 2013-05-31 2017-06-16 Sorrento Therapeutics, Inc. 与pd-1结合的抗原结合蛋白
RS63571B9 (sr) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva
PL3081576T3 (pl) 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
KR20190015377A (ko) 2016-06-02 2019-02-13 브리스톨-마이어스 스큅 컴퍼니 불응성 호지킨 림프종에서의 니볼루맙을 사용한 pd-1 차단

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518826A (ja) 2012-05-15 2015-07-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔ Ｐｄ−１／ｐｄ−ｌ１シグナル伝達を破壊することによる癌免疫療法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Blood, 2014, Vol.121, No.21, 290
Curr. Opin. Pharmacol., 2015, Vol.23, pp.32-38
Eur. J. Heamatol., Published online 2016.05.30, Vol.97, pp.219-227
J. Clin. Oncol., Published online 2016.05.20, Vol.34, No.15_suppl, 7535
Lancet Oncol., 2013, Vol.14, pp.1348-1356
N. Engl.J. Med., 2015, Vol.371, No.4, pp.311-319
日薬理誌, 2015, Vol.146, pp.106-114

Also Published As

Publication number Publication date
HRP20230864T1 (hr) 2023-11-10
RS64388B1 (sr) 2023-08-31
PL3463457T3 (pl) 2023-08-21
EP4248990A2 (en) 2023-09-27
KR20190015377A (ko) 2019-02-13
JP7568698B2 (ja) 2024-10-16
JP2023025012A (ja) 2023-02-21
US20250134996A1 (en) 2025-05-01
SMT202300290T1 (it) 2023-11-13
EP3463457B1 (en) 2023-06-28
SI3463457T1 (sl) 2023-09-29
FI3463457T3 (fi) 2023-09-12
US11083790B2 (en) 2021-08-10
DK3463457T3 (da) 2023-10-02
PT3463457T (pt) 2023-09-07
KR20230038318A (ko) 2023-03-17
EP3463457A1 (en) 2019-04-10
JP2019517504A (ja) 2019-06-24
LT3463457T (lt) 2023-09-11
HUE062398T2 (hu) 2023-10-28
US20190290757A1 (en) 2019-09-26
EP4248990A3 (en) 2024-01-03
JP2025020119A (ja) 2025-02-12
CN109475633A (zh) 2019-03-15
WO2017210453A1 (en) 2017-12-07
US20220025049A1 (en) 2022-01-27
ES2954139T3 (es) 2023-11-20

Similar Documents

Publication Publication Date Title
JP7568698B2 (ja) 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断
US20250154257A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody
US20220298243A1 (en) Anti-pd-1 antibody in combination with an anti-cd30 antibody in cancer treatment
US20160347836A1 (en) Treatment of hodgkin&#39;s lymphoma using an anti-pd-1 antibody
EP4386005A2 (en) Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
US20250154258A1 (en) Methods of treating urothelial carcinoma using an anti-pd-1 antibody
HK40098571A (en) Pd-1 blockade with nivolumab in refractory hodgkin&#39;s lymphoma
US20250179182A1 (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody drug conjugate
EA046895B1 (ru) Способ и набор для лечения субъекта, страдающего от опухоли, происходящей из неходжкинской лимфомы, или опухоли, происходящей из лимфомы ходжкина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221108

R150 Certificate of patent or registration of utility model

Ref document number: 7175198

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250